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Abstract
Background: TNF alpha blockade agents like infliximab are actually the treatment of choice for those rheumatoid arthritis
(RA) patients who fail standard therapy. However, a considerable percentage of anti-TNF alpha treated patients do not show
a significant clinical response. Given that new therapies for treatment of RA have been recently approved, there is a pressing
need to find a system that reliably predicts treatment response. We hypothesized that the analysis of whole blood gene
expression profiles of RA patients could be used to build a robust predictor to infliximab therapy.
Methods and Findings: We performed microarray gene expression analysis on whole blood RNA samples from RA patients
starting infliximab therapy (n=44). The clinical response to infliximab was determined at week 14 using the EULAR criteria.
Blood cell populations were determined using flow cytometry at baseline, week 2 and week 14 of treatment. Using
complete cross-validation and repeated random sampling we identified a robust 8-gene predictor model (96.6% Leave One
Out prediction accuracy, P=0.0001). Applying this model to an independent validation set of RA patients, we estimated an
85.7% prediction accuracy (75–100%, 95% CI). In parallel, we also observed a significantly higher number of CD4+CD25+
cells (i.e. regulatory T cells) in the responder group compared to the non responder group at baseline (P=0.0009).
Conclusions: The present 8-gene model obtained from whole blood expression efficiently predicts response to infliximab in
RA patients. The application of the present system in the clinical setting could assist the clinician in the selection of the
optimal treatment strategy in RA.
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Introduction
Rheumatoid Arthritis (RA) is one of the most prevalent
autoimmune diseases in the world and is characterized by the
chronic inflammation of the synovial joints. In RA, the sustained
inflammatory process progressively destroys the articular cartilage
and subchondral bone leading, in many cases, to major functional
disability [1]. The origin of the disease is unknown but it is actually
accepted that it is caused by the complex interaction of a genetic
susceptibility background and environmental factors [2,3]. This
lack of knowledge, however, has not prevented the development of
pharmacological treatments that can efficiently control the
progression of the disease. The clearest exponent of this success
has been the treatment of active RA through the neutralization of
Tumor Necrosis Factor alpha (TNF-alpha) cytokine.
Infliximab was the first TNF alpha blocker for RA treatment to
be clinically tested and is a genetically constructed IgG1 murine-
human chimeric monoclonal antibody that binds both to the
soluble subunit as well as the membrane-bound precursor of TNF-
alpha [4]. Like the other two approved anti-TNF blockers,
adalimumab and etanercept, infliximab has proven to be an
efficacious treatment for disease activity control in patients with
RA [1]. There is however a subgroup of RA patients (ranging 20–
40%) who, in spite of synovial TNF-alpha production do not
respond to general TNF blockade therapy [5]. In these cases,
alternative approved biological therapies like rituximab or
abatacept, would be more beneficial for the patient [6]. Therefore,
a major goal in RA treatment is to identify a reliable response
predictor to anti-TNF alpha therapy.
Several systems have been assayed for the prediction of clinical
response to anti-TNF alpha in RA patients. The most direct
approach, the measurement of clinical variables at the beginning of
treatment, has been found to be a weak predictor of the type of
response [7]. For this reason, the search for informative biomarkers
is actually been favoured. None of the biomarkers analyzed to date
hasbeen found to havesufficientpredictive power tobe usefulinthe
practical setting [8]. However, the recent introduction of high-
throughput analytical systems is now expected to be a major
breakthroughinbiomarkerdiscovery.Inparticular, gene expression
microarrays have already shown to be a very powerful technology
for the identification of gene expression profiles predictive of disease
evolution or treatment response [9,10].
In the present study we have used microarray technology for the
identification and validation of a whole blood gene expression
profile predictive of the response to infliximab in RA patients.
With the implementation of a standardized processing methodol-
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powerful 8-gene model predictor for the response to infliximab
treatment in RA patients.
Methods
Patients
From January 2005 to June 2007, those RA patients with active
disease (i.e. defined as a Disease Activity Score (DAS28) .3.2) from
the Rheumatology Unit of the Hospital Universitari Vall d’Hebron
(Barcelona, Spain) that were going to start infliximab therapy were
considered for inclusion in the present study. The DAS28 score is a
combined index to measure the disease activity in patients with RA
and it has been extensively used in clinical trials as well as daily
clinical practice[11]. It uses the number oftenderandswollen joints
(from a total of 28 joints), a measure of systemic inflammatory
activity (erythrocyte sedimentation rate in this case), as well as a
general health assessment of the patient using a visual analog scale.
The inclusion criteria for RA patients in the present study were 1)
fulfilment of the revised 1987 American Rheumatism Association
criteria [12] 2) naı ¨ve to anti-TNF alpha treatment 3) receiving
concomitant metothrexate (MTX) treatment of #20 mg/wk or
maximum tolerable and 4) concomitant therapy with prednisolone
(GC, dose #10 mg/day or equivalent) and NSAID 5) having stable
MTX, GC and NSAID doses during the previous 4 weeks to the
inclusion in the study 6) having discontinued previous DMARDs at
least 4 weeks prior to the inclusion 7) fulfilment of all standard
inclusion criteriadefined forinfliximab treatment. Exclusioncriteria
were 1) patients positive for hepatitis B or C virus (active or inactive)
2) fulfilment of all standard exclusion criteria defined for infliximab
treatment. All patients signed an informed consent at the time of
enrolment, and all the procedures followed were in accordance with
the ethical standards of the Institut de Recerca HospitalUniversitari
Vall d’Hebron ethics committee and with the Helsinki Declaration.
Clinical procedures
Clinical variables associated with disease activity were recorded
at the time of the first infliximab infusion (wk0) and at weeks 2 and
14 of treatment. The assessment of the clinical response to
infliximab therapy was performed at week 14 using the European
League Against Rheumatism (EULAR) criteria [13]. The EULAR
criteria is the reference method for determining the response to
treatment in RA that combines both an absolute value of disease
activity (DAS28) as well as the relative improvement [14]. With this
methodpatientsareclassified into good,moderate orpoor response.
This method uses two variables 1) the baseline DAS28 score (i.e.
week 0 in this case) and 2) the variation in the DAS28 activity score
due to treatment (i.e. variation between week 14 and week 0). In the
present study we used a binary outcome variable: ‘‘poor’’ response
individuals were classified as ‘‘non-responders’’, and ‘‘moderate’’ or
‘‘good’’ response individuals were classified as ‘‘responders’’.
Blood collection and RNA extraction
Blood samples were extracted at weeks 0 (RNA and flow
cytometry analyses), 2 and 14 (flow cytometry analyses only) of
infliximab treatment from all patients. All blood RNA samples were
obtained, preserved and extracted following a well-defined protocol
we specificallydevelopedforthisstudy(Supporting InformationS1).
Blood RNA was preserved at the same time of venipuncture using
the PAXgene Blood RNA System (PreAnalytix, Switzerland).
Samples were store frozen at 280uC until RNA isolation. Total
RNA was extracted using the PAXgene RNA Isolation kit (Qiagen,
Valencia, CA, USA) following the recommended protocol. We
extractedthe RNAonly from thosepatients that reachedthe time of
treatment response determination (i.e. week 14, n=44 patients).
TheRNAextractionwasperformedsimultaneouslyinallsamplesto
minimize the technical variation associated with this step and RNA
integrity was assessed using the Nano total RNA kit from the 2100
BioAnalyzer system (Agilent, Santa Clara, CA, USA).
Microarray analysis
Whole-genome gene expression analysis was performed using
the Illumina Human-6 v1 Beadchip array system (Illumina, San
Diego, CA, USA). This microarray platform measures the gene
expression levels of more than 47,000 transcripts using 50-mer
DNA probes fixed on a bead-based system. At the same time the
microarray data was being acquired, an updated version of the
Illumina Beadchip was launched. This new version included a
redesign of several probe sequences, principally, those not
belonging to the RefSeq database. Therefore, we restricted the
microarray analysis only on those probes that were still considered
as valid (Illumina in-house data, available online).
Only good quality blood RNAs (i.e. 28S/18S ratio close to 2,
RNA Integrity Number .8) were subsequently processed using
the Illumina gene expression assay. Biotin-labeled cRNA was
hybridized to Sentrix whole genome beadchips and scanned on
the Illumina BeadStation 500x. The raw intensity data was
obtained from the scanned arrays using the BeadStudio software
version 1.4.02 (Illumina, San Diego, CA, USA), using the default
probe summarization and background substraction methods. The
statistical analyses were performed using the open-source statistical
environment ‘‘R’’ and the associated Bioconductor project
libraries for genomic analyses [15].
The log2-transformed intensity values were normalized using
the quantile normalization method [16] implemented in the affy
package. Quality control analysis of the normalized data identified
an outlying gene expression profile which was excluded from
further analyses (Supporting Information S1). Before analyzing the
normalized data, we performed a filtering step in order to exclude
uninformative genes. Those probes for which all gene-expression
values were under the lowest 5
th percentile of the global gene-
expression values were considered as non-expressed and discarded
(n=4,150). Probes with a low variability (coefficient of variation
,0.03, n=14,701) were also removed. All microarray data is in
accordance with MIAME guidelines and is accessible through
GEO database reference GSE12051.
Unsupervised analysis of RA gene expression patterns
Before building the response predictor, we sought to determine if
the whole blood gene expression profiles at week 0 already clustered
RA patients according to their response to anti-TNF alpha.
Unsupervised classification techniques like hierarchical clustering
analysis are suitable for this purpose. However, they are generally
used without any assessment of the statistical robustness of the
identified clusters [17]. In the present study we use the resampling-
based method implemented in the Bioconductor package ‘‘cluster-
Stab’’ to determine both the optimal number of clusters and the
statistical significance of the final clustering [18]. The differential
gene expression between the significant clusters was performed
using the Welch’s t-test implemented in the multtest package.
Response predictor building and validation
Predictor building and validation (Figure 1) was performed using
the established robust methodology for microarray prediction: first,
the global sample was randomly divided into a training sample (2/3
ofthesample,29patients)andavalidationsample(1/3ofthesample,
14 patients). Given the moderate sample size, we used balanced
sampling to ensure a similar proportion of responders and non-
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optimal classifier method and its parameters through Leave-One-Out
Cross Validation (LOOCV). This repeated cross validation method is
a powerful means to evaluate the performance of a classifier without
incurringingeneselectionbias[19].Inparticular,thepredictorgenes
are independently determined at each round of cross validation
without using the left-out sample. The new model is then applied to
this external sample to obtain an independent estimate of the
predictor’s accuracy.
In the present study we evaluated Support Vector Machines,
Diagonal Discriminant Analysis (Diagonal Linear Discriminant
Analysis or DLDA and Diagonal Quadratic Discriminant Analysis
or DQDA), Random Forests and k–Nearest Neighbours using the
Bioconductor libraries e1071, ipred, randomForest and class, respec-
tively. Details on the parameters used in the classifier evaluation
are included in Supporting Information S1.
In order to select the final model between equally good predictor
models we calculated a permutation P value associated with their
prediction accuracy. This step avoids model selection bias, that is, to
select simpler models only based in their lower complexity [20].
Finally, we used the independent validation set to determine the
accuracy of the predictor. Bootstrap resampling was used to calculate
the 95% confidence intervals associated to the estimated precision
accuracy using the percentile estimation method [21].
Figure 1. Methodology for building and validating a robust microarray predictor. The construction of robust microarray-based predictors
must necessarily follow a series of steps in order to avoid analytical biases and ensure a real applicability of the model. First, the original sample is
split in two subsamples: the training sample and the validation sample. In the training sample we seek to find the optimal classifier; complete cross-
validation (leave-one out cross validation in our case) gives an unbiased measure of the power of each tested model. In the case that we find similarly
good performing models, a resampling method (i.e. permutation testing) can be used to objectively select the most robust between them. Only once
we have chosen the optimal model we will apply it to the validation sample. Since we have not used the information from this independent sample
in building the predictor, the accuracy determined from this sample set is an optimal estimation of the power of the model in a real setting. A
resampling method (i.e. bootstrap analysis) can be used to estimate the confidence intervals associated with the predictor accuracy.
doi:10.1371/journal.pone.0007556.g001
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In all RA patients included in the study, we performed cell
cytometry analyses the same day of blood extraction for
microarray analysis. We determined the main leukocyte subpop-
ulations (i.e. neutrophils, lymphocytes and monocytes) as well as
red blood cell (RBC) and platelet counts. Within the lymphocyte
subpopulation, we performed a complete evaluation of different
subsets including CD3+8+, CD3+4+, CD4+CD8+ (i.e. double
positive lymphocytes), CD4+CD28+ (i.e. active CD4+ T cells [22])
and CD4+CD25+ (i.e. regulatory CD4+ T cells [23]). Briefly, cells
were stained by direct immunofluorescence using monoclonal
antibodies conjugated with fluorochromes FITC, Phycoerythrin,
Pycoerythrin-cyanin 5 and ECD. Isotype-matched immunoglob-
ulins with no reactivity against surface markers and the
fluorochrome combination were used as negative controls. After
antibody incubation and subsequent erythrocyte lysis, we
performed cell count acquisition using the EPICS-XL MCL
(Coulter, Germany). Statistical significance was assessed using t-
test or paired t-test when appropriate. In the study of cell
cytometry changes along time, those individuals with missing data
in any of the three time points (i.e. week 0, 2 and 14) were
excluded from the paired analysis.
Results
Assessment of clinical response of infliximab treated
patients
During the 2 year-recruitment period 48 RA patients with
active disease starting infliximab therapy were selected for the
present study. From these, 44 patients reached week 14 of
treatment whilst 4 were withdrawn (for septic arthritis, myocardial
infarction, infusion reaction and voluntary discontinuation in each
case). Using the binary classification described previously 7
patients were categorized as ‘‘Non-Responders’’ and 37 as
‘‘Responders’’ (Table 1).
Unsupervised analysis of baseline gene expression
profiles
The optimal clustering number parameter was found to be k=2
(Supporting Information S1). Whilst one of the patient clusters was
statistically stable (86% of 1,000 resamplings the original cluster
appears) the other grouping of patients appeared to be relatively
unstable (40% of 1,000 resamplings the original cluster appears). We
also found that unsupervised classification at baseline did not
segregate patients according to their treatment response (Supporting
Information S1).
In order to understand the origin of the observed patient grouping
we performed the differential gene expression analysis between both
clusters. Although Gene Ontology (GO) analysis did not show any
statistically overrepresented GO term (data not shown), we could
identify several erythrocyte-related genes overexpressed in one of the
clusters (Supporting Information S1). We subsequently compared the
blood cell counts and haemoglobin concentration between both
groups and found that the latter was statistically significant (mean
haemoglobin concentration of cluster 1=13.05 g/l vs. mean of
cluster 2=11.41 g/l, P value =0.0008, Supporting Information S1).
Importantly, this confounder was not present when comparing
haemoglobin concentrations between patients classified according to
their response to infliximab (P=0.71).
Microarray predictor building and testing
After applying the gene filtering steps, a total of n=3,364 genes
were selected for the microarray predictor building and testing. The
exhaustive analysis of different classifier algorithms using the Leave
One Out Cross-Validation method showed an overall good
predictive performance (Supporting Information S1). Using either
Support Vector Machines, Linear Discriminant Analysis, Random
Forests or k-Nearest Neighbours (kNN) classifiers, the best
prediction accuracy attainable was, at least, of 89.6%. From these,
the kNN classifier reached a nearly perfect prediction accuracy (1
misclassification out of 29, 96.6% prediction accuracy) in an 8 gene
model using either 3, 4 or 5 nearest neighbours (Figure 2). The only
misclassified individual in the LOOCV analysis was a responder
individual that was incorrectly classified as a non-responder. All
infliximab non-responder patients were correctly predicted.
In order to select the final classifier between the equally
performing kNN models, we calculated a permutation P value for
the prediction accuracy. All three models were highly significant,
confirming the robustness of the classifier method (P=0.0001,
P=0.0002, and P=0.0003, for 3-, 4- and 5- nearest neighbours
models, respectively. We finally selected for validation the 3-nearest
neighbour kNN model, since it had the most significant P value.
We next sought to identify the consistency of each of the
predictor genes throughout the different cross validation steps
(Figure 3). We found that 6 of the 8 predictor genes -HLA-DRB3,
SH2D1B, GNLY, CAMP, SLC2A3 and IL2RB- were selected
more than 80% of the time, and the remaining 2 -MXD4 and
TLR5- were selected more than 50% of the time. This finding
clearly demonstrates the strong correlation between the gene
expression of each predictor gene with the response outcome.
Validation of the microarray predictor
Applying the final 8 gene predictor model in and independent
dataset of 14 patients, 12 of them were correctly classified indicating
an 86% prediction accuracy. Bootstrap determination of the 95%
confidence interval for the estimated prediction accuracy was 75 to
100%. The incorrectly classified individuals were 1 infliximab
responder and 1 non-responder, thus giving an estimated sensitivity
and specificity of 91.6% and 50%, respectively. Taking into account
the performance of the predictor both in the LOOCV and in the
external validation, we estimated a 94.4% sensitivity and an 85.7%
specificity of the present predictor model.
Flow cytometry analysis of blood cells according to
infliximab response
Comparing the flow cytometry measures between response
groups at each treatment time, we found responders to have a






Age (years) 52.73611.37 51.84610.85 57.43613.77 0.34
Sex (women:men) 38 5 32:4 6 1 0.57
RA duration (years) 14.3269.82 13.0469.04 19.0612 0.30
DAS28 week 0 5.9461.17 5.98161.20 5.7661.05 0.62
DAS28 week 14 4.0961.18 3.8361.07 5.4461.047 0.0002
CCP (% positive) 86.05% 86.11% 83.33% 0.99
RF (% positive) 58.14% 55.55% 71.42% 0.68
Plus-minus values are means 6 SD. The DAS28 score was defined according to
the European League against Rheumatism criteria. *P-value calculated using
Welch’s t-test or Fisher’s exact test when appropriate.
doi:10.1371/journal.pone.0007556.t001
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baseline (P=0.0009, Figure 4). We also found that, in this group,
the number of neutrophils at week 2 was significantly lower
compared to the non responder group (4.1 e9/L vs. 2.9 e9/L,
respectively, P=0.032; see Supporting Information S2).
The analysis of the flow cytometry changes associated to anti-
TNF alpha treatment identified a major effect in the responder
group. In this group, platelet and neutrophil counts showed a
highly significant reduction along the two treatment weeks
(P,0.001 in all cases). Response to infliximab was also associated
Figure 2. Error rates associated to different parameter values for kNN classifier. From left to right, predictor models with increasing
number of genes and increasing number of nearest-neighbours are evaluated in the training dataset using LOOCV. The 8 gene model under 3, 4 or 5
nearest neighbours (green color) were found to be the optimal classifiers with only 1 patient misclassified out of 29 (0.034 error rate).
doi:10.1371/journal.pone.0007556.g002
Figure 3. Percentage of inclusion of all genes selected through LOOCV. The present plot shows the percentage that each gene is selected
amongst the top 8 genes after 29 rounds of LOOCV. It can be seen that, from all genes, the 8-predictor gene group is systematically selected
indicating a strong correlation with the outcome. The remaining genes seem to be selected on a random basis.
doi:10.1371/journal.pone.0007556.g003
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treatment (P=0.03). No statistically significant variation was
observed in the CD4+ lymphocyte compartment, although an
increasing trend in CD4+CD25+ cell numbers could be observed
in the non-responder group (Figure 4).
We evaluated the use of CD4+CD25+ as predictors of anti-TNF
alpha therapy using generalized linear model fitting. However, the
performance of the identified predictor was not as good as the
microarray gene expression predictor (71% prediction accuracy,
50% specificity and 75% sensitivity).
Discussion
Using whole blood gene expression profiles of RA patients we
have built and validated a robust predictor of response to
infliximab therapy. We have identified an eight gene expression
model with a leave-one out cross validation accuracy of 96.5% and
an independent validation accuracy of 86.5% (CI: 75–100%). In
parallel, we have found a significantly higher number of baseline
CD4+CD25+ T cells in the responder group compared to the non-
responder group (P,0.0009).
Figure 4. Flow cytometry CD4+CD25+ lymphocyte counts from responders and non responders to infliximab at weeks 0, 2 and 14.
Non responders had a significantly lower CD4+CD25+ lymphocyte fraction than responders at baseline (P=0.0009). During the treatment this CD4+
subpopulation increased, ending with similar levels to the responder group.
doi:10.1371/journal.pone.0007556.g004
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two main steps: 1) unbiased selection of the predictor model
parameters and 2) estimation of the predictor model generalisa-
bility [19]. In the present study we have taken into account these
two fundamental steps in the building and validation of the
microarray predictor to infliximab therapy. First, using complete
cross-validation we have identified the optimal model using the
kNN algorithm. The high prediction accuracy already determined
at this step is an unbiased measure of the strong predictive power
of the model. Another important measure of the prognostic value
of a microarray predictor is the stability of the predictive genes
[24]. We have found that the group of 8 predictor genes is
preferentially selected at each independent round of cross
validation demonstrating the strong correlation between gene
expression and the type of response; some genes –HLA-DRB3,
SH2D1B and GNLY-, are even selected at all rounds. Second, we
have confirmed the generalisability of the predictor by applying it
to an independent validation set. The confidence interval for the
prediction accuracy was relatively narrow, emphasizing the good
power of the model to predict the response to anti-TNF alpha
therapy. Taking together the estimates in the internal (LOOCV)
and external validation, the present predictor has an estimated
94.4% sensitivity and 85.7% specificity for the prediction of
infliximab response which is the highest performance reached by a
biomarker for this therapy to date.
To date, levels of systemic TNF alpha, Rheumatoid Factor,
anti-CCP antibodies and C-Reactive Protein have been analyzed
for their association with treatment response, but the results have
shown either inconsistent or with no practical use in the clinical
setting [8]. Also, several genetic markers like TNF alpha promoter
SNPs or the shared epitope have been tested for their
predictability but with yet inconclusive results [25,26]. In the
present study we have used the whole blood gene expression
profile as a biomarker for infliximab response prediction. Blood is
an ideal biomarker tissue both for being noninvasive and for its
practical application in the clinical settings [27]. Although a
relatively complex tissue, whole blood gene expression has been
shown to be informative of particular disease conditions [28,29].
In RA, previous studies using blood mononuclear cell isolates and
microarray technology have been performed in the search for a
response predictor to anti-TNF therapy [30,31,32]. However,
none of these have entirely followed the robust predictor
methodology described here and therefore their findings should
be considered with caution [19]. In the present study we show
that, whilst unsuitable for unsupervised classification, the whole
blood gene expression can be useful for the efficient prediction of a
response to a particular treatment, in this case, systemic anti-TNF
alpha blockade. In the present study we have also developed and
implemented a standardized methodology which should facilitate
its extended use in different clinical settings.
The study of patients segregated according to anti-TNF alpha
response can be useful to identify relevant biological mechanisms in
RA [5]. We have found that infliximab responders have a higher
number of CD4+CD25+ T cells (i.e. Tregs) than non-responders at
baseline. Tregs are powerful regulators of autoimmune responses
and there is increasing evidence for their implication in several
autoimmune disorders including RA [33,34]. Recently, a new
mechanism involving this cell type has been proposed for anti-TNF
therapy effect [34]. In this model, TNF blockade would elicit the
formation of de novo Tregs from peripheral CD4+CD25- effector
lymphocytes, which would in turn reduce the proinflammatory
activity of the disease. However, we have not found a significant
increase in this CD4+ compartment in the response group along
treatment; this tendency is rather observed in the non-responder
group. From our observations, itseems that response to infliximab is
more favourable under higher numbers of this cell type at baseline.
Interestingly, one of the predictor genes overexpressed in non-
responders, IL2RB, has been also found to be significantly
overexpressed in peripheral mononuclear cells of infliximab non-
responders at baseline [32]. IL2RB, together with CD25 (also
known as IL2RA), forms a medium affinity receptor for the
lymphocyte growth factor IL2. Specific studies are needed to define
the precise origin of this differential gene expression and its relation
to treatment response. The remaining predictor genes have all been
linked to the immune response or even to autoimmunity
[35,36,37,38,39] but, to date, this is the first evidence of their
association to anti-TNF alpha treatment response.
The present study is an important step towards the management
of RA through molecular biomarkers. Recently, new therapies for
the control of RA have been developed and several others are soon
going to become available. With this increase in treatment options,
there is a pressing need to find systems that reliably predict the
efficacy of a particular treatment for a particular patient. The
present 8-gene predictor model for infliximab treatment can be a
powerful tool for therapy individualization in RA and future
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